GLP-1 Agonists Show Biopsy-Confirmed MASH Resolution; FDA Grants Accelerated Approval

GLP-1 receptor agonists, the drug class behind semaglutide, are now showing biopsy-confirmed benefits in MASH, the inflammatory form of fatty liver disease, with a 72-week trial reporting resolution in 62.9% of participants on semaglutide versus 34.3% on placebo.

News-Medical reported on the accumulated evidence behind those numbers, drawing on recent meta-analyses of randomized controlled trials published in journals including Liver International and Pharmaceutics. The stakes are high: metabolic dysfunction-associated steatotic liver disease, or MASLD, affects up to 38% of the global population and is projected to reach 55% by 2040, according to Tavaglione and Loomba.

MASH — formerly called NASH — is the stage where liver fat is joined by inflammation and hepatocellular ballooning, a form of liver cell swelling and injury. Left to progress, fibrosis can advance to cirrhosis, liver failure, or hepatocellular carcinoma. Cardiovascular disease, News-Medical noted, contributes substantially to death and illness in these patients, which is why treatments that address both metabolism and liver pathology matter.

Semaglutide Approved for Advanced Liver Disease: First GLP-1 Drug to Treat MASH with Fibrosis — Georgian Medical Journal

Regulators have already moved. In August 2025, the US Food and Drug Administration granted accelerated approval to Wegovy (semaglutide) for adults with noncirrhotic MASH and moderate-to-advanced fibrosis (stages F2–F3), to be used alongside a reduced-calorie diet and increased physical activity — with continued approval contingent on confirmed clinical benefit, per the FDA’s 2026 prescribing information.

Drugs Reverse Inflammation and Reduce Scarring in Moderate Cases

  • These drugs appear to reverse liver inflammation and, in some patients, reduce scarring — but the evidence is strongest for people with moderate scarring who do not yet have cirrhosis.
  • Liver enzyme improvements on blood tests do not prove the liver is healing; biopsy-confirmed changes are the real benchmark.
  • Side effects are real and mostly digestive: nausea, vomiting, diarrhea, and constipation, often managed by slowly increasing the dose.

Trials Show Weight Loss Drives MASH Improvement

GLP-1 receptor agonists mimic a gut hormone. Their mechanism of action — the way a drug produces its effect — is threefold: they increase glucose-dependent insulin secretion, promote satiety, and slow gastric emptying.

Weight loss is the primary route by which they improve MASH, News-Medical reported, though experimental work suggests anti-inflammatory and antifibrotic pathways may contribute, partly independent of weight loss. Whether GLP-1 receptors on human hepatocytes, the liver’s main cells, mediate a direct benefit remains uncertain.

The headline data come from the 72-week ESSENCE analysis, in participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis — moderate and advanced scarring. Semaglutide 2.4 mg once weekly produced MASH resolution without worsening fibrosis in 62.9% of participants versus 34.3% on placebo. Fibrosis improved without worsening MASH in 36.8% versus 22.4%. Earlier analyses had lacked sufficient biopsy evidence for a fibrosis benefit; ESSENCE strengthened the case, particularly for semaglutide.

Recent meta-analyses of randomized controlled trials — including one in the Journal of the Canadian Association of Gastroenterology — support both histological endpoints regulators consider acceptable for accelerated approval in MASH clinical trials: resolution of MASH without fibrosis worsening, and at least one-stage fibrosis improvement without MASH worsening.

There is a hard limit to the optimism. A 48-week semaglutide trial in compensated MASH-related cirrhosis — cirrhosis without overt complications — did not show improved fibrosis or MASH resolution versus placebo. Benefits seen in noncirrhotic fibrosis cannot be extrapolated to cirrhosis, News-Medical reported.

Additional coverage from Medical Xpress, reporting on work published in Lancet Gastroenterology & Hepatology, carried the same caution alongside a note of persistence from researcher Loomba: “These findings strengthen the need to continue studying semaglutide and other metabolic therapies in advanced liver disease.”

Dual Agonists Show Larger Effects but Lack Head-To-Head Proof

Research is expanding past single-receptor drugs. These incretin-based therapies include GLP-1 receptor agonists alone as well as dual and triple combinations that add GIP and/or glucagon receptor activity. Some subgroup analyses suggest larger effects with dual agonists on body weight and hepatic outcomes, but these comparisons draw on different trials and few studies — they do not establish superiority, and head-to-head trials are needed, News-Medical reported.

Tavaglione and Loomba frame these incretin-based therapies as promising particularly for patients with coexisting obesity or type 2 diabetes, noting pleiotropic effects — actions in multiple organs — including cardiovascular and renal benefits.

What the Evidence Still Cannot Say

Three gaps matter most. First, the current evidence comes from phase 2 and phase 3 trials focused on histology-assessed hepatic endpoints, leaving longer-term clinical outcomes unresolved. Second, trials differ substantially in design, population, duration, and comparators, making direct comparisons difficult. Third, a 2026 meta-analysis found no statistically significant benefits in weight or fibrosis in the small subgroup of patients without type 2 diabetes.

References

  • Mantovani, A., et al. (2025). A meta-analysis of randomized controlled trials finds that glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis. Liver International 45(9).
  • Tornea, D. A., et al. (2026). A systematic review and meta-analysis examining how GLP-1 agonists affect patients with metabolic-associated steatotic liver disease. Pharmaceutics 18(1).
  • Potter, K. J., et al. (2025). Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in nonalcoholic fatty liver disease. Journal of the Canadian Association of Gastroenterology 8(2).
  • Huang, X., et al. (2025). Gastrointestinal adverse events associated with GLP-1 receptor agonists in MASLD. Frontiers in Medicine 12.
  • U.S. Food and Drug Administration. (2026). Wegovy prescribing information — MASH indication, accelerated approval.

This article is informational and does not constitute medical advice. Consult a qualified healthcare professional about diagnosis and treatment decisions.

Photo of author

Health Desk

Health Desk at Archyde.

Weakening the PING Attractor Produces Physiologically Realistic Gamma Rhythms in Silico